Inflammation-related enzymes and cytokine regulators

Inflammation-related enzymes and cytokine regulators constitute a diverse functional group of proteins that mediate the initiation, maintenance, and resolution of inflammatory responses. This category includes key enzymes such as cyclooxygenases (COX-1 and COX-2), which catalyze the production of prostaglandins, and lipoxygenases (LOX), involved in leukotriene synthesis (StatPearls, 2023). It also encompasses a wide array of cytokines, such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), which act as intercellular signaling molecules to coordinate immune cell activity (NCBI, 2012). Dysregulation of these enzymes and cytokines is a hallmark of numerous chronic diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Therapeutic strategies targeting these molecules range from non-steroidal anti-inflammatory drugs (NSAIDs) to advanced biologics and kinase inhibitors (Nature Reviews Immunology, 2017). While highly effective in reducing disease activity, modulating these targets can lead to significant safety concerns, most notably an increased risk of opportunistic infections due to suppressed immune surveillance.

Other names

Inflammatory mediatorsPro-inflammatory enzymes and cytokinesInflammation regulatorsInflammatory signaling molecules

Pharmacological intervention involves the inhibition of enzymatic activity (e.g., COX-1/2 inhibition), the neutralization of circulating cytokines via monoclonal antibodies, or the blockade of cytokine receptors and downstream signaling kinases like JAK (StatPearls, 2023; Nature Reviews Immunology, 2017).